Π‘ΡΡΡΠΊΡΡΡΠ½ΠΎ-ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠ° ΠΠΠ-Π³ΠΈΡΠ°Π·Ρ ΠΌΠΈΠΊΡΠΎΡΠΈΠ½Π° Π
ΠΠ°Π½Π½Π°Ρ ΡΠ°Π±ΠΎΡΠ° ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π° ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΈΡΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΏΠ΅ΠΏΡΠΈΠ΄Π½ΠΎΠ³ΠΎ Π°Π½ΡΠΈΠ±ΠΈΠΎΡΠΈΠΊΠ°ΠΌΠΈΠΊΡΠΎΡΠΈΠ½Π° Π. ΠΠ΅Π½Ρ, ΠΎΡΠ²Π΅ΡΠ°ΡΡΠΈΠ΅ Π·Π° ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΡ ΠΈ ΡΡΡΠΎΠΉΡΠΈΠ²ΠΎΡΡΡ ΠΊ ΠΌΠΈΠΊΡΠΎΡΠΈΠ½ΡΠ Π·Π°ΠΊΠΎΠ΄ΠΈΡΠΎΠ²Π°Π½Ρ Π½Π° ΠΏΠ»Π°Π·ΠΌΠΈΠ΄Π΅ΠΏΡΠΈΡΡΡΡΡΠ²ΡΡΡΠ΅ΠΉ Π² Π½Π΅ΠΊΠΎΡΠΎΡΡΡ ΡΡΠ°ΠΌΠΌΠ°Ρ ?. ΡΠΎ//'. ΠΠ½ΡΠΈΠ±ΠΈΠΎΡΠΈΠΊ, ΠΎΠ±Π»Π°Π΄Π°Π΅Ρ1 Π±Π°ΠΊΡΠ΅ΡΠΈΡΠΈΠ΄Π½ΡΠΌΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ΠΌ. ΠΈ> Π°ΠΊΡΠΈΠ²Π΅Π½: Π²" ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ: Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π° Π³ΡΠ°ΠΌΠΎΡΡΠΈΡΠ°ΡΠ΅Π»ΡΠ½ΡΡ Π±Π°ΠΊΡΠ΅ΡΠΈΠΉ! ΠΡΠ΅Π»ΡΠΉ ΠΌΠΈΠΊΡΠΎΡΠΈΠ½ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅Ρ ΡΠΎΠ±ΠΎΠΉ 47-Π°ΠΌΠΈΠ½ΠΎΠΊΠΈΡΠ»ΠΎΡΠ½ΡΠΉ ΠΏΠ΅ΠΏΡΠΈΠ΄… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
- Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- ΠΡΠ΄Π΅ΡΠΆΠΊΠ°
- ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°
- ΠΡΡΠ³ΠΈΠ΅ ΡΠ°Π±ΠΎΡΡ
- ΠΠΎΠΌΠΎΡΡ Π² Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΠΈ
Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- Π‘ΠΠΠ‘ΠΠ Π‘ΠΠΠ ΠΠ©ΠΠΠΠ ΠΠΠ©ΠΠ― Π₯ΠΠ ΠΠΠ’ΠΠ ΠΠ‘Π’ΠΠΠ Π ΠΠΠΠ’Π« ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ ΡΠ°Π±ΠΎΡΡ
- Π¦Π΅Π»ΠΈ ΠΈ Π·Π°Π΄Π°ΡΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ
- ΠΠ°ΡΡΠ½Π°Ρ Π½ΠΎΠ²ΠΈΠ·Π½Π° ΠΈ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ ΡΠ°Π±ΠΎΡΡ
- ΠΡΠ±Π»ΠΈΠΊΠ°ΡΠΈΠΈ ΠΈ Π°ΠΏΡΠΎΠ±Π°ΡΠΈΡ ΡΠ°Π±ΠΎΡΡ
- Π‘ΡΡΡΠΊΡΡΡΠ° ΠΈ ΠΎΠ±ΡΠ΅ΠΌ ΡΠ°Π±ΠΎΡΡ
- ΠΠΠΠΠ ΠΠΠ’ΠΠ ΠΠ’Π£Π Π« i. ΠΠΠ-ΡΠΎΠΏΠΎΠΈΠ·ΠΎΠΌΠ΅ΡΠ°Π·Ρ ΠΈ ΠΈΡ ΡΡΠ½ΠΊΡΠΈΠΈ Π² ΠΊΠ»Π΅ΡΠΊΠ΅
- ΠΠΠ-ΡΠΎΠΏΠΎΠΈΠ·ΠΎΠΌΠ΅ΡΠ°Π·Ρ ΡΠΈΠΏΠ° 1Π ΠΎΠ±ΡΠ°ΡΠ½Π°Ρ Π³ΠΈΡΠ°Π·Π°
- ΠΠΠ-ΡΠΎΠΏΠΎΠΈΠ·ΠΎΠΌΠ΅ΡΠ°Π·Ρ ΡΠΈΠΏΠ° 1Π
- ΠΠΠ-ΡΠΎΠΏΠΎΠΈΠ·ΠΎΠΌΠ΅ΡΠ°Π·Ρ II ΡΠΈΠΏΠ°
- ΠΠ½ΠΈΡΠΈΠ°ΡΠΈΡ ΡΠ΅ΠΏΠ»ΠΈΠΊΠ°ΡΠΈΠΈ
- Π Π΅ΠΏΠ»ΠΈΠΊΠ°ΡΠΈΡ ΠΠΠ
- Π’ΡΠ°Π½ΡΠΊΡΠΈΠΏΡΠΈΡ
- Π Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΡ ΠΠΠ
- Π’ΠΎΠΏΠΎΠΈΠ·ΠΎΠΌΠ΅ΡΠ°Π·Ρ ΠΈ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΡ Ρ ΡΠΎΠΌΠ°ΡΠΈΠ½Π°
II. ΠΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΡ ΠΠΠ-ΡΠΎΠΏΠΎΠΈΠ·ΠΎΠΌΠ΅ΡΠ°Π· 30 ΠΠ°ΠΌΠΏΡΠΎΡΠ΅ΡΠΈΠ½ ΠΈ Π΄ΡΡΠ³ΠΈΠ΅ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΡ ΡΠΎΠΏΠΎΠΈΠ·ΠΎΠΌΠ΅ΡΠ°Π·Ρ I 30 Π₯ΠΈΠ½ΠΎΠ»ΠΎΠ½Ρ 33 ΠΡΠΌΠ°ΡΠΈΠ½Ρ 36 ΡΠΈΠΊΠ»ΠΎΡΠΈΠ°Π»ΠΈΠ΄ΠΈΠ½Ρ 37 ΠΠΌΠΈΠ½ΠΎΠ±Π΅Π½Π·ΠΈΠΌΠΈΠ΄Π°Π·ΠΎΠ»Ρ 38 Π‘ΠΈΠΌΠΎΡΠΈΠΊΠ»ΠΈΠ½ΠΎΠ½Ρ 38 ΠΊΠ»Π΅ΡΠΎΡΠΈΠ΄ΠΈΠ½ 39 Π΄ΠΈΡΡΠ°ΠΌΠΈΡΠΈΠ½, Π ΠΈ Π΄ΡΡΠ³ΠΈΠ΅ Π²Π΅ΡΠ΅ΡΡΠ²Π°, ΡΠ²ΡΠ·ΡΠ²Π°ΡΡΠΈΠ΅ΡΡ Ρ ΠΌΠ°Π»ΠΎΠΉ Π±ΠΎΡΠΎΠ·Π΄ΠΊΠΎΠΉ ΠΠΠ 40 Π¨>Π 41 Π±Π£ΠΉ! 42 ΠΠΈΠΊΡΠΎΡΠΈΠ½ Π
ΠΠΠ’ΠΠ ΠΠΠΠ« Π ΠΠΠ’ΠΠΠ« ΠΠ‘Π‘ΠΠΠΠΠΠΠΠΠ― ΠΠ±ΠΎΡΡΠ΄ΠΎΠ²Π°Π½ΠΈΠ΅
Π Π°ΡΡ ΠΎΠ΄Π½ΡΠ΅ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ
Π Π΅Π°ΠΊΡΠΈΠ²Ρ ΠΈ ΡΠ΅ΡΠΌΠ΅Π½ΡΡ Π±ΡΡΠ΅ΡΠ½ΡΠ΅ ΡΠ°ΡΡΠ²ΠΎΡΡ
ΠΠΈΠΊΡΠΎΠ±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΡΠ΅Π΄Ρ
ΠΠ°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΠ΅ ΡΡΠ°ΠΌΠΌΡ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ΅Π»Π°ΠΊΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΠΠ Π΄Π»Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΠΠ-Π³ΠΈΡΠ°Π·Ρ in vitro
ΠΠΏΡΡ ΠΏΠΎ ΡΠ°ΡΡΠ΅ΠΏΠ»Π΅Π½ΠΈΡ ΠΠΠ ΠΠΠ-Π³ΠΈΡΠ°Π·ΠΎΠΉ IN VITRO Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΌΠΈΠΊΡΠΎΡΠΈΠ½Π° ΠΈΠ· ΠΊΠ»Π΅ΡΠΎΠΊ Π. ΡΠΎΠΈ ΠΈ ΠΠΠΠ₯-Π°Π½Π°Π»ΠΈΠ·
ΠΠ°ΡΡ-ΡΠΏΠ΅ΠΊΡΡΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· (ΠΠΠΠΠ ΠΈΡΠ°Π½Π΄Π΅ΠΌΠ½Π°Ρ ΠΠ‘)
Π₯ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΡΠΈΠ½Π° Π
ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π°Π½ΡΠΈΠ±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π°Π½ΡΠΈΠ±ΠΈΠΎΡΠΈΠΊΠΎΠ² ΠΈ Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠ°ΡΠΈΡ SOS-otbeta
Π‘Π°ΠΉΡ-ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΌΡΡΠ°Π³Π΅Π½Π΅Π·
ΠΠ»Π΅ΠΊΡΡΠΎΡΠΎΡΠ΅Π· ΠΠΠ Π² Π°Π³Π°ΡΠΎΠ·Π½ΠΎΠΌ Π³Π΅Π»Π΅
ΠΠΈΠ³ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΡΠΎΠ΄ΡΠΊΡΠ° Π°ΠΌΠΏΠ»ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ Π² ΠΏΠ»Π°Π·ΠΌΠΈΠ΄Π½ΡΠ΅ Π²Π΅ΠΊΡΠΎΡΠ°
Π Π΅ΡΡΡΠΈΠΊΡΠΈΡ
ΠΡΠΈΠ³ΠΎΡΠΎΠ²Π»Π΅Π½ΠΈΠ΅ Ρ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈ ΠΊΠΎΠΌΠΏΠ΅ΡΠ΅Π½ΡΠ½ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ Π. ΡΠΎΠΈ
Π’ΡΠ°Π½ΡΡΠΎΡΠΌΠ°ΡΠΈΡ Π·Π°ΠΌΠΎΡΠΎΠΆΠ΅Π½Π½ΡΡ ΠΊΠΎΠΌΠΏΠ΅ΡΠ΅Π½ΡΠ½ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ Π. ΡΠΎΠΈ
ΠΠ½Π°Π»ΠΈΠ· ΠΊΠΎΠ»ΠΎΠ½ΠΈΠΉ Π. ΡΠΎΠΈ
ΠΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠ»Π°Π·ΠΌΠΈΠ΄Π½ΠΎΠΉ ΠΠΠ (ΠΌΠΈΠ½ΠΈΠΏΡΠ΅ΠΏ)
Π‘Π΅ΠΊΠ²Π΅Π½ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅
ΠΠ΅ΡΠ΅ΠΎΡΠ°ΠΆΠ΄Π΅Π½ΠΈΠ΅ ΠΠΠ ΡΠΏΠΈΡΡΠΎΠΌ
ΠΠΊΡΡΡΠ°ΠΊΡΠΈΡ ΠΠΠ ΡΠ΅Π½ΠΎΠ»ΠΎΠΌ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ΅ΠΏΠ»ΠΈΠΊΠ°ΡΠΈΠΈ Π² ΠΏΠ΅ΡΠΌΠ΅Π°Π±ΠΈΠ»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΡ ΠΊΠ»Π΅ΡΠΊΠ°Ρ Π. COLI
Π ΠΠΠ£ΠΠ¬Π’ΠΠ’Π« Π ΠΠΠΠ’Π« Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·Π°ΡΠΈΡ Π²ΡΠ΄Π΅Π»ΡΠ΅ΠΌΠΎΠ³ΠΎ ΠΈΠ· ΠΊΠ»Π΅ΡΠΎΠΊ ΠΌΠΈΠΊΡΠΎΡΠΈΠ½Π° Π Ρ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΡΠΈΠ½Π° Π
Π©Π΅Π»ΠΎΡΠ½ΠΎΠΉ Π³ΠΈΠ΄ΡΠΎΠ»ΠΈΠ· ΠΌΠΎΠ΄ΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΠΏΠΎ Ser52 ΠΌΠΈΠΊΡΠΎΡΠΈΠ½Π° ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π°Π΅Ρ Π½Π°Π»ΠΈΡΠΈΠ΅ ΡΠ»ΠΎΠΆΠ½ΠΎΡΡΠΈΡΠ½ΠΎΠΉ ΡΠ²ΡΠ·ΠΈ Π² ΠΌΠΈΠΊΡΠΎΡΠΈΠ½Π΅ «X»
ΠΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π²Π΅ΡΠ΅ΡΡΠ²Π° X ΠΈ ΠΏΠ΅ΡΠ΅Ρ ΠΎΠ΄ X→N
ΠΠ°ΠΏΡΠ°Π²Π»Π΅Π½Π½ΡΠΉ ΠΌΡΡΠ°Π³Π΅Π½Π΅Π· ΠΌΠΈΠΊΡΠΎΡΠΈΠ½Π° Π
Π‘ΡΡΡΠΊΡΡΡΠ½ΠΎ-ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΌΠΈΠΊΡΠΎΡΠΈΠ½Π° Π
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- Norrby, R., et al., The bacterial challenge: time to react. ECDC/EMEA Joint Technical Report, 2009.
- Fischbach, M.A. and C.T. Walsh, Antibiotics for Emerging Pathogens. Science, 2009. 325(5944): p. 1089−1093.
- Melby, J.O., N.J. Nard, and D.A. Mitchell, Thiazole/oxazole-modified microcins: complex natural products from ribosomal templates. Current Opinion in Chemical Biology, 2011. 15(3): p. 369−378.
- Mitchell, D.A., et al., Structural and Functional Dissection of the Heterocyclic Peptide Cytotoxin Streptolysin S. Journal of Biological Chemistry, 2009. 284(19): p. 13 004−13 012.
- Morris, R.P., et al., Ribosomally Synthesized Thiopeptide Antibiotics Targeting Elongation Factor Tu. Journal of the American Chemical Society, 2009.131(16): p. 5946−5955.
- Onaka, H., et al., Cloning and characterization of the goadsporin biosynthetic gene cluster from Streptomyces sp. TP-A0584. Microbiology, 2005.151(12): p. 3923−3933.
- Molloy, E.M., et al., Streptolysin S-like virulence factors: the continuing sagA. Nat Rev Micro, 2011. 9(9): p. 670−681.
- Walsh, C.T., M.G. Acker, and A.A. Bowers, Thiazolyl Peptide Antibiotic Biosynthesis: A Cascade of Post-translational Modifications on Ribosomal Nascent Proteins. Journal of Biological Chemistry, 2010. 285(36): p. 27 525−27 531.
- Mcintosh, J.A. and E.W." Schmidt, Marine Molecular Machines: Heterocyclization in Cyanobactin Biosynthesis. ChemBioChem, 2010.11(10): p. 1413−1421.
- Gonzalez, DJ., et al., Clostridiolysin S, a Post-translationally Modified Biotoxin from" Clostridium botulinum. Journal of Biological Chemistry, 2010. 285(36): p. 28 220−28 228.
- Wieland Brown, L.C., et al., Thirteen posttranslational modifications convert a 14-residue Β¦ peptide into the antibiotic thiocillin. Proceedings of the National Academy of Sciences, 2009.106(8): p. 2549−2553.
- Scholz, R., et al., Plantazolicin, a Novel Microcin B17/Streptoiysin S-Like Natural Product from Bacillus amyloliquefaciens FZB42. J. Bacterid., 2011.193(1): p. 215−224.
- Oman, T.J. and W.A. van der Donk, Follow the leader: the use of leader peptides to guide natural product biosynthesis. Nat Chem Biol, 2010. 6(1): p. 9−18.
- Li, Y.-M., et al., From Peptide Precursors to Oxazole and Thiazole-Containing Peptide Antibiotics: Microcin B17Synthase. Science, 1996. 274(5290): p. 1188−1193.
- Kelleher, N.L., C.L. Hendrickson, and C.T. Walsh, Posttranslational Heterocyclization of Cysteine and Serine Residues in the Antibiotic Microcin B17: Distributivity and Directionalityt. Biochemistry, 1999. 38(47): p. 15 623−15 630.
- Milne, J.C., et al., Cofactor Requirements and Reconstitution Of Microcin B17 Synthetase: A Multienzyme Complex that Catalyzes the Formation of Oxazoles and Thiazoles in the Antibiotic Microcin B17t. Biochemistry, 1999. 38(15): p. 4768−4781.
- Herrero, M. and F. Moreno, Microcin B17 Blocks DNA Replication and Induces the SOS System In Escherichia coli. Journal of General Microbiology, 1986.132(2): p. 393−402.
- Yorgey, P., et al., Posttranslational modifications in microcin B17 define an additional class of DNA gyrase inhibitor. Proceedings of the National Academy of Sciences, 1994. 91(10): p. 4519−4523.
- Allali, N., et al., The Highly Conserved TldD and TldE Proteins of Escherichia coli Are Involved in Microcin B17 Processing and in CcdA Degradation. J. Bacteriol., 2002. 184(12): p. 3224−3231.
- Heddle, J.G., et al., The antibiotic microcin B17 is a DNA gyrase poison: characterisation of the mode of inhibition. Journal of Molecular Biology, 2001. 307(5): p. 1223−1234.
- Pierrat, O.A. and A. Maxwell, The Action of the Bacterial Toxin Microcin B17. Journal of Biological Chemistry, 2003. 278(37): p. 35 016−35 023.
- Pierrat, O.A. and A. Maxwell, Evidence for the Role of DNA Strand Passage in the Mechanism of Action of Microcin B17 on DNA Gyrase~i~. Biochemistry, 2005. 44(11): p. 4204−4215.
- Parks, W.M., et al., The action of the bacterial toxin, microcin B17, on DNA gyrase. Biochimie, 2007. 89(4): p. 500−507.
- Wang, J.C., Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol, 2002. 3(6): p. 430−40.
- Kirkegaard, K. and J.C. Wang, BacterialΒ¦ DNA topoisomerase I can relax positively supercoiled DNA containing a single-stranded loop. J Mol Biol, 1985.185(3): p. 625−37.
- Baker, N.M., R. Rajan, and A. Mondragon, Structural studies of type I topoisomerases. Nucleic Acids Res, 2009. 37(3): p. 693−701.
- Lima, C.D., J.C. Wang, and A. Mondragon, Three-dimensional structure of the 67K N-terminalfragment of E. coli DNA topoisomerase I. Nature, 1994. 367(6459): p. 138−46.
- Zhang, Z., B. Cheng, and Y.C. Tse-Dinh, Crystal structure of a covalent intermediate in DNA cleavage and rejoining by Escherichia coli DNA topoisomerase I. Proc Natl Acad Sci USA, 2011.108(17): p. 6939−44.
- Schmidt, B.H., et al., A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases. Nature. 465(7298): p. 641−4.
- Dekker, N.H., et al., The mechanism of type IA topoisomerases. Proc Natl Acad Sci USA, 2002. 99(19): p. 12 126−31.
- Rodriguez, A.C., Studies of a positive supercoiling machine. Nucleotide hydrolysis and a multifunctional «latch» in the mechanism of reverse gyrase. J Biol Chem, 2002. 277(33): p. 29 865−73.
- Ganguly, A., et al., The latch modulates nucleotide and DNA binding to the helicase-like domain of Thermotoga maritima reverse gyrase and is required for positive DNA supercoiling. Nucleic Acids Res. 39(5): p. 1789−800.
- Champoux, J.J., DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem, 2001. 70: p. 369−413.
- Koster, D.A., et al., Friction and torque govern the relaxation of DNA supercoils by eukaryotic topoisomerase IB. Nature, 2005. 434(7033): p. 671−4.
- Woo, M.H., et al., Locking the DNA topoisomerase I protein clamp inhibits DNA rotation and induces cell lethality. Proc Natl Acad Sci USA, 2003.100(24): p. 13 767−72.
- Carey, J.F., et al., DNA relaxation by human topoisomerase I occurs in the closed clamp conformation of the protein. Proc Natl Acad Sci USA, 2003.100(10): p. 5640−5.
- Bates, A.D., J.M. Berger, and A. Maxwell, The ancestral role of ATP hydrolysis in type Ih topoisomerases: prevention of DNA double-strand breaks. Nucleic Acids Res.
- Rybenkov, V.V., et al., Simplification of DNA topology below equilibrium values by type II topoisomerases. Science, 1997. 277(5326): p. 690−3.
- Bates, A.D. and A. Maxwell, Energy coupling in type II topoisomerases: why do they hydrolyze ATP? Biochemistry, 2007. 46(27): p. 7929−41.
- Stuchinskaya, T., et al., How do type II topoisomerases use ATP hydrolysis to simplify DNA topology beyond equilibrium? Investigating the relaxation reaction of nonsupercoiling type II topoisomerases. J Mol Biol, 2009. 385(5): p. 1397−408.
- Baxter, J., et al. Positive supercoiling of mitotic DNA drives decatenation by topoisomerase II in eukaryotes. Science. 331(6022): p. 1328−32.
- Dong, K.C. and J.M. Berger, Structural basis for gate-DNA recognition and bending by type IIA topoisomerases. Nature, 2007. 450(7173): p. 1201−5.
- Liu, L.F. and J.C. Wang, DNA-DNA gyrase complex: the wrapping of the DNA duplex outside the enzyme. Cell, 1978.15(3): p. 979−84.
- Ruthenburg, A.J., et' al., A superhelical spiral in the Escherichia coli DNA gyrase A C-terminal domain imparts unidirectional supercoiling bias. J Biol Chem, 2005. 280(28): p. 26 177−84.
- Kampranis, S.C. and A. Maxwell, Conversion of DNA gyrase into a conventional type II topoisomerase. Proc Natl Acad Sei USA, 1996. 93(25): p. 14 416−21.
- Kampranis, S.C., A.D. Bates, and A. Maxwell, A model for the mechanism of strand passage by DNA gyrase. Proc Natl Acad Sei USA, 1999. 96(15): p. 8414−9.
- Ullsperger, C. and N.R. Cozzarelli, Contrasting enzymatic activities of topoisomerase IV and DNA gyrase from Escherichia coli. J Biol Chem, 1996. 271(49): p. 31 549−55.
- Corbett, K.D., et al., The structural basis for substrate specificity in DNA topoisomerase IV. J Mol Biol, 2005. 351(3): p. 545−61.
- Francine B, P., Protein Splicing of Inteins and Hedgehog Autoproteolysis: Structure, Function, and Evolution. Cell, 1998. 92(1): p. 1−4.
- Corbett, K.D., P. Benedetti, and J.M. Berger, Holoenzyme assembly and ATP-mediated conformational dynamics of topoisomerase VI. Nat Struct Mol Biol, 2007. 14(7): p. 6119.
- Rampakakis, E., et al., Replication initiation and DNA topology: The twisted life of the origin. J Cell Biochem. 110(1): p. 35−43.
- Bermejo, R., et al., Topi- and Top2-mediated topological transitions at replication forks ensure fork progression and stability and prevent DNA damage checkpoint activation. Genes Dev, 2007. 21(15): p. 1921−36.
- Kegel, A., et al., Chromosome length influences replication-induced topological stress. Nature. 471(7338): p. 392−6.
- Tadesse, S., et al., Genetic interaction of the SMC complex with topoisomerase IV in Bacillussubtilis. Microbiology, 2005.151(Pt 11): p. 3729−37.
- Hayama, R. and K.J. Marians, Physical and functional interaction between the condensin MukB and the decatenase topoisomerase IV in Escherichia coli. Proc Natl Acad Sei USA. 107(44): p. 18 826−31.
- Li, Y., et al., Escherichia coli condensin MukB stimulates topoisomerase IV activity by a direct physical interaction. Proc Natl Acad Sei USA. 107(44): p. 18 832−7.
- Coelho, P.A., J. Queiroz-Machado, and C.E. Sunkel, Condensin-dependent localisation of topoisomerase II to an axial chromosomal structure is required for sister chromatid resolution during mitosis. J Cell Sei, 2003.116(Pt 23): p. 4763−76.
- Suski, C. and K.J. Marians, Resolution of converging replication forks by RecQ and topoisomerase III. Mol Cell, 2008. 30(6): p. 779−89.
- Lodge, J.K., T. Kazic, and D.E. Berg, Formation of supercoiling domains In plasmid pBR322. J Bacteriol, 1989.171(4): p. 2181−7.
- Cook, D.N., et al., Dynamics of DNA supercoiling by transcription in Escherichia coli. Proc Natl Acad Sei USA, 1992. 89(22): p. 10 603−7.
- Liu, L.F. and J.C. Wang, Supercoiling of the DNA template during transcription. Proc Natl Acad Sei USA, 1987. 84(20): p. 7024−7.
- Wang, J.C. and A.S. Lynch, Transcription and DNA supercoiling. Curr Opin Genet Dev, 1993. 3(5): p. 764−8.
- Drolet, M., Growth inhibition mediated by excess negative supercoiling: the interplay between transcription elongation, R-hop formation and DNA topology. Mol Microbiol, 2006. 59(3): p. 723−30.
- Cook, P.R., The organization of replication and transcription. Science, 1999. 284(5421): p. 1790−5.
- Vreugde, S., et al., Nuclear myosin VI enhances RNA polymerase ll-dependent transcription. Mol Cell, 2006. 23(5): p. 749−55.
- Mitchell, J.A. and P. Fraser, Transcription factories are nuclear subcompartments that remain in the absence of transcription. Genes Dev, 2008. 22(1): p. 20−5.
- Perales, R. and D. Bentley, «Cotranscriptionality»: the transcription elongation complex as a nexus for nuclear transactions. Mol Cell, 2009. 36(2): p. 178−91.
- French, S.L., et al., Distinguishing the roles of Topoisomerases I and II in relief of transcription-induced torsional stress in yeast rRNA genes. Mol Cell Biol. 31(3): p. 48 294.
- Ju, B.G., et al., A topoisomerase llbeta-mediated dsDNA break required for regulated transcription. Science, 2006. 312(5781): p. 1798−802.
- Varga-Weisz, P.D., et al., Chromatin-remodelling factor CHRAC contains the ATPases ISWI and topoisomerase II. Nature, 1997. 388(6642): p. 598−602.
- LeRoy, G., et al., Purification and characterization of a human factor that assembles and remodels chromatin. J Biol Chem, 2000. 275(20): p. 14 787−90.
- Perillo, B., et al., DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science, 2008. 319(5860): p. 202−6.
- Tsutsui, K.M., et al., Expression dynamics and functional implications of DNA topoisomerase II beta in the brain. Anat Sci Int, 2006. 81(3): p. 156−63.
- Tsutsui, K., et al., Involvement of DNA topoisomerase llbeta in neuronal differentiation. J Biol Chem, 2001. 276(8): p. 5769−78.
- Sano, K., et al., Topoisomerase IIOI Activates a Subset of Neuronal Genes that Are Repressed inAT-Rich Genomic Environment. PLoS One, 2008. 3(12): p. e4103.
- Tuduri, S., et al., Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nat Cell Biol, 2009. 11(11): p. 131 524.
- Durand-Dubief, M., et al., Topoisomerase I regulates open chromatin and controls gene expression in vivo. EMBO J. 29(13): p. 2126−34.
- Shykind, B.M., et al., Topoisomerase I enhances TFIID-TFIIA complex assembly during activation of transcription. Genes Dev, 1997.11(3): p. 397−407.
- Dayani, Y., G. Simchen, and M. Lichten, Meiotic Recombination Intermediates Are Resolved with Minimal Crossover Formation during Return-to-Growth, an Analogue of the Mitotic Cell Cycle. PLoS Genet. 7(5): p. el002083.
- Chen, C.F. and S.J. Brill, Binding and activation of DNA topoisomerase III by the Rmil subunit. J Biol Chem, 2007. 282(39): p. 28 971−9.
- Lai, M.S., et al., Rmil, a member of the Sgsl-Top3 complex in budding yeast, contributes to sister chromatid cohesion. EMBO Rep, 2007. 8(7): p. 685−90.
- Wu, L. and I.D. Hickson, The Bloom’s syndrome helicase suppresses crossing over during homologous recombination. Nature, 2003. 426(6968): p. 870−4.
- Yang, J., et al., Human topoisomerase lllalpha is a single-stranded DNA decatenase that is stimulated by BLM and RMIl. J Biol Chem. 285(28): p. 21 426−36.
- Plank, J.L., J. Wu, and T.S. Hsieh, Topoisomerase lllalpha and Bloom’s helicase can resolve a mobile double Holliday junction substrate through convergent branch migration. Proc Natl Acad Sci USA, 2006.103(30): p. 11 118−23.
- Kwan, K.Y., P.B. Moens, and J.C. Wang, Infertility and aneuploidy in mice lacking a type IA DNA topoisomerase III beta. Proc Natl Acad Sci USA, 2003.100(5): p. 2526−31.
- Gasser, S.M., et al., Metaphase chromosome structure. Involvement of topoisomerase II. J Mol Biol, 1986.188(4): p. 613−29.
- Gasser, S.M. and U.K. Laemmli, The organisation of chromatin loops: characterization of a scaffold attachment site. EMBO J, 1986. 5(3): p. 511−8.
- Adachi, Y., E. Kas, and U.K. Laemmli, Preferential, cooperative binding of DNA topoisomerase II to scaffold-associated regions. EMBO J, 1989. 8(13): p. 3997−4006.
- Cockerill, P.N. and W.T. Garrard, Chromosomal loop anchorage of the kappa immunoglobulin gene occurs next to the enhancer in a region containing topoisomerase IIsites. Cell, 1986. 44(2): p. 273−82.
- Masliah, G., et al., Identification of intrinsic dynamics in a DNA sequence preferentially cleaved by topoisomerase II enzyme. J Mol Biol, 2008. 381(3): p. 692−706.
- Hizume, K., et al., Topoisomerase II, scaffold component, promotes chromatin compaction in vitro in a linker-histone Hl-dependent manner. Nucleic Acids Res, 2007. 35(8): p. 2787−99.
- Christensen, M.O., et al., Dynamics of human DNA topoisomerases llalpha and llbeta in living cells. J Cell Biol, 2002.157(1): p. 31−44.
- Gimenez-Abian, J.F. and D.J. Clarke, Replication-coupled topoisomerase II templates the mitotic chromosome scaffold? Cell Cycle, 2003. 2(3): p. 230−2.
- Takagi, K., et al., Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters. Mol Cancer Ther, 2007. 6(12 Pt 1): p. 3229−38.
- Pommier, Y. and M. Cushman, The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives. Mol Cancer Ther, 2009.
- Teicher, B.A., Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem Pharmacol, 2008. 75(6): p. 1262−71.
- Strumberg, D., et al., Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff. Mol Cell Biol, 2000. 20(11): p. 3977−87.
- Dexheimer, T.S., et al., Tyrosyl-DNA phosphodiesterase as a target for anticancer therapy. Anticancer Agents Med Chem, 2008. 8(4): p. 381−9.
- Zhang, A., et al., A protease pathway for the repair of topoisomerase ll-DNA covalent complexes. J Biol Chem, 2006. 281(47): p. 35 997−6003.
- Cortes Ledesma, F., et al., A human 5'-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage. Nature, 2009. 461(7264): p. 674−8.
- Kreuzer, K.N. and N.R. Cozzarelli, Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase subunit A: effects on deoxyribonucleic acid replication, transcription, and bacteriophage growth. J Bacterid, 1979.140(2): p. 424−35.
- Laponogov, I., et al., Structural basis of gate-DNA breakage and resealing by" type II topoisomerases. PLoS One, 2010. 5(6): p. ell338.
- Tran, J.H. and G.A. Jacoby, Mechanism of plasmid-mediated quinolone resistance. Proc Natl Acad Sci USA, 2002. 99(8): p. 5638−42.
- Hegde, S.S., et al., A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA. Science, 2005. 308(5727): p. 1480−3.
- Garrido, M.C., et al., The export of the DNA replication inhibitor Microcin B17 provides immunity for the host cell. EMBO J, 1988. 7(6): p. 1853−62.
- Lewis, R.J., et al., The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X-ray crystallography. EMBO J, 1996.15(6): p. 1412−20.
- Flatman, R.H., et al., Structure-activity relationships of aminocoumarin-type gyrase and topoisomerase IV inhibitors obtained by combinatorial biosynthesis. Antimicrob Agents Chemother, 2006. 50(4): p. 1136−42.
- Oblak, M., M. Kotnik, and T. Solmajer, Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents. Curr Med Chem, 2007.14(19): p. 2033−47.
- Mani, N., et al., In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class. Antimicrob Agents Chemother, 2006. 50(4): p. 1228−37.
- Oppegard, L. M, et al., In vivo and in vitro patterns of the activity of simocyclinone D8, an angucyclinone antibiotic from Streptomyces antibioticus. Antimicrob Agents Chemother, 2009. 53(5): p. 2110−9.
- Sadiq, A.A., et al., Anti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase II. Invest New Drugs, 2010. 28(1): p. 20−5.
- Edwards, M.J., et al., A crystal structure of the Afunctional antibiotic simocyclinone D8, bound to DNA gyrase. Science, 2009. 326(5958): p. 1415−8.
- Sissi, C., et al., Mapping simocyclinone D8 interaction with DNA gyrase: evidence for a new binding site on GyrB. Antimicrob Agents Chemother, 2010. 54(1): p. 213−20.
- Gatto, B., et al., The topoisomerase II poison clerocidin alkylates non-paired guanines of DNA: implications for irreversible stimulation of DNA cleavage. Nucleic Acids Res, 2001. 29(20): p. 4224−30.
- Pan, X.S., et al., Clerocidin selectively modifies the gyrase-DNA gate to induce irreversible and reversible DNA damage. Nucleic Acids Res, 2008. 36(17): p. 5516−29.
- Storl, K., et al., Minor-groove binders are inhibitors of the catalytic activity of DNA gyrases. FEBS Lett, 1993. 317(1−2): p. 157−62.
- Dao-Thi, M.H., et al., Molecular basis of gyrase poisoning by the addiction toxin CcdB. J Mol Biol, 2005. 348(5): p. 1091−102.
- San Millan, J.L., R. Kolter, and F. Moreno, Plasmid genes required for microcin B17 production. J Bacteriol, 1985.163(3): p. 1016−20.
- Zambie, D.B., et al., The McbB component of microcin B17 synthetase is a zinc metalloprotein. Biochemistry, 2000. 39(51): p. 16 190−9.
- Destoumieux-Garzon, D., J. Peduzzi, and S. Rebuffat, Focus on modified microcins: structural features and mechanisms of action. Biochimie, 2002. 84(5−6): p. 511−9.
- Wang, R., F.P. Healey, and J. Myers, Amperometric measurement of hydrogen evolution in chlamydomonas. Plant Physiol, 1971.48(1): p. 108−10.
- Herrero, M. and F. Moreno, Microcin B17 blocks DNA replication and induces the SOS system in Escherichia coli. J Gen Microbiol, 1986.132(2): p. 393−402.
- Glenn, T.M., et al., Production of a myocardial depressant factor in cardiogenic shock. Am Heart J, 1971. 82(1): p. 78−85.
- Heddle, J.G., et al., The antibiotic microcin B17 is a DNA gyrase poison: characterisation of the mode of inhibition. J Mol Biol, 2001. 307(5): p. 1223−34.
- Curran, J.P. and J.S. Wang, Fatal intracranial hemorrhage as the first sign of hemophilia B in an infant. Am J Dis Child, 1971.122(1): p. 63−5.
- Sinha Roy, R., et al., In vivo processing and antibiotic activity of microcin B17 analogs with varying ring content and altered bisheterocyclic sites. Chem Biol, 1999. 6(5): p. 30 518.
- Zambie, D.B., et al., In vitro characterization of DNA gyrase inhibition by microcin B17 analogs with altered bisheterocyclic sites. Proc Natl Acad Sci USA, 2001. 98(14): p. 7712−7.
- Roy, R.S., et al., Role of the microcin B17 propeptide in substrate recognition: solution structure and mutational analysis of McbAl-26. Chemistry &- Biology, 1998. 5(4): p. 217−228.
- Vizan, J.L., et al., The peptide antibiotic microcin B17 induces double-strand cleavage of
- DNA mediated by E. coli DNA gyrase. EMBO J, 1991.10(2): p. 467−476.1.vina, M., A.P. Pugsiey, and F. Moreno, Identification, Mapping, Cloning and
- Characterization of a Gene (sbmA) Required for Microcin B17 Action on Escherichia coli
- K12. Journal of General Microbiology, 1986.132(6): p. 1685−1693.
- Drlica, K., et al., Quinolones: Action and Resistance Updated. Current Topics in Medicinal
- Chemistry, 2009. 9(11): p. 981−998.
- Couturier, M., E.M. Bahassi, and L. Van Melderen, Bacterial death by DNA gyrase poisoning. Trends in Microbiology, 1998. 6(7): p. 269−275.
- Perler, F.B., M.-Q. Xu, and H. Paulus, Protein splicing and autoproteoiysis mechanisms. Current Opinion in Chemical Biology, 1997.1(3): p. 292−299.
- Saleh, L. and F.B. Perler, Protein splicing In Cis and In Trans. The Chemical Record, 2006. 6(4): p. 183−193.
- Zamble, D.B., et al., In vitro characterization of DNA gyrase inhibition by microcin B17 analogs with altered bisheterocyclic sites. Proceedings of the National Academy of Sciences, 2001. 98(14): p. 7712−7717.
- Maxwell, A., DNA gyrase as a drug target. Biochem Soc Trans, 1999. 27(2): p. 48−53. Pommier, Y., et al., DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol, 2010.17(5): p. 421−33.